Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/ijo.IJO_639_20 http://scihub22266oqcxt.onion/10.4103/ijo.IJO_639_20 32317431!7350468!32317431     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Indian+J+Ophthalmol 2020 ; 68 (5): 693-702 Nephropedia Template TP {{tp|p=32317431|t=2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |pdf=|usr=}}{{32317431}} gab.com Text Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future JO: Indian J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=32317431 #FOAvip A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed. Twit Text FOAVip Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future ????Indian J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=32317431 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32317431 #FOAvip English Wikipedia <ref>{{Cite pmid|32317431}}</ref> Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future #MMPMID32317431 Shetty R; Ghosh A; Honavar SG; Khamar P; Sethu S Indian J Ophthalmol 2020[May]; 68 (5): 693-702 PMID32317431show ga A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed. |*Betacoronavirus/physiology[MESH] |Animals[MESH] |COVID-19[MESH] |Coronavirus Infections/epidemiology/immunology/prevention & control/*therapy[MESH] |Humans[MESH] |Immunity, Active[MESH] |Morbidity[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/epidemiology/immunology/prevention & control/*therapy[MESH] |SARS-CoV-2[MESH]Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Pre(epmc).pdf DeepDyve Pubget Overpricing